CY1119411T1 - Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων - Google Patents
Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτωνInfo
- Publication number
- CY1119411T1 CY1119411T1 CY20171100687T CY171100687T CY1119411T1 CY 1119411 T1 CY1119411 T1 CY 1119411T1 CY 20171100687 T CY20171100687 T CY 20171100687T CY 171100687 T CY171100687 T CY 171100687T CY 1119411 T1 CY1119411 T1 CY 1119411T1
- Authority
- CY
- Cyprus
- Prior art keywords
- novel
- compounds
- phosphone
- selection
- manufacture
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- -1 magnesium alkoxide Chemical class 0.000 abstract 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Παρέχεται νέα μέθοδος για συστηματική εξέταση προφαρμάκων αναλόγων μεθοξυφωσφονικού νουκλεοτιδίου για να πιστοποιούνται προφάρμακα που στοχεύουν εκλεκτικώς επιθυμητούς ιστούς με αντι-ιική ή κατά του όγκου δραστικότητα. Η μέθοδος αυτή έχει οδηγήσει στην πιστοποίηση νέων μεικτών εστέρα-αμιδικών του ΡΜΡΑ για ρετροϊική ή hepadna-ιική θεραπεία, συμπεριλαμβανομένων ενώσεων της σύνταξης (5a) που έχουν ομάδες υποκατάστατη όπως ορίζεται στο παρόν. Παρέχονται συνθέσεις αυτών των νέων ενώσεων σε φαρμακευτικώς αποδεκτά έκδοχα και χρήση αυτών στην θεραπεία και προφύλαξη. Επίσης, παρέχεται βελτιωμένη μέθοδος για την χρήση αλκοξειδίου μαγνησίου για την παρασκευή υλικών έναρξης και ενώσεων για χρήση στο παρόν.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22002100P | 2000-07-21 | 2000-07-21 | |
EP01961695.2A EP1301519B2 (en) | 2000-07-21 | 2001-07-20 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119411T1 true CY1119411T1 (el) | 2018-03-07 |
Family
ID=22821718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2016008C CY2016008I1 (el) | 2000-07-21 | 2016-04-12 | Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων |
CY20171100687T CY1119411T1 (el) | 2000-07-21 | 2017-06-28 | Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2016008C CY2016008I1 (el) | 2000-07-21 | 2016-04-12 | Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων |
Country Status (37)
Country | Link |
---|---|
US (10) | US20040018150A1 (el) |
EP (3) | EP2682397B1 (el) |
JP (4) | JP4651264B2 (el) |
KR (2) | KR100749160B1 (el) |
CN (2) | CN1291994C (el) |
AP (1) | AP1466A (el) |
AU (3) | AU8294101A (el) |
BE (1) | BE2016C018I2 (el) |
BG (1) | BG66037B1 (el) |
BR (1) | BRPI0112646B8 (el) |
CA (3) | CA2416757C (el) |
CY (2) | CY2016008I1 (el) |
CZ (2) | CZ304886B6 (el) |
DK (2) | DK2682397T3 (el) |
EA (1) | EA004926B1 (el) |
EE (1) | EE05366B1 (el) |
ES (2) | ES2627903T3 (el) |
FR (1) | FR16C0013I2 (el) |
HK (2) | HK1054238A1 (el) |
HR (2) | HRP20160074B1 (el) |
HU (2) | HU230960B1 (el) |
IL (1) | IL153658A0 (el) |
IS (1) | IS2985B (el) |
LT (2) | LT2682397T (el) |
LU (1) | LU93029I2 (el) |
MX (1) | MXPA03000587A (el) |
NL (1) | NL300803I2 (el) |
NO (6) | NO336718B1 (el) |
NZ (3) | NZ523438A (el) |
OA (1) | OA12393A (el) |
PL (1) | PL213214B1 (el) |
PT (2) | PT1301519E (el) |
SI (2) | SI2682397T1 (el) |
TR (1) | TR200300055T2 (el) |
UA (1) | UA75889C2 (el) |
WO (1) | WO2002008241A2 (el) |
ZA (1) | ZA200210271B (el) |
Families Citing this family (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4651264B2 (ja) * | 2000-07-21 | 2011-03-16 | ギリアード サイエンシーズ, インコーポレイテッド | ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。 |
US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
PL374525A1 (en) * | 2001-11-14 | 2005-10-31 | Biocryst Pharmaceuticals, Inc. | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
TWI332956B (en) * | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
JP4476811B2 (ja) | 2002-05-13 | 2010-06-09 | メタバシス・セラピューティクス・インコーポレイテッド | Pmeaおよびそのアナログの新規ホスホン酸系プロドラッグ |
US20040224917A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
MXPA05011296A (es) * | 2003-04-25 | 2006-01-24 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de la cinasa. |
CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
US7300924B2 (en) * | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
WO2005002626A2 (en) * | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7427636B2 (en) * | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
JP2007508843A (ja) * | 2003-10-24 | 2007-04-12 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用化合物の同定のための方法および組成物 |
WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
WO2005044279A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
US20080287471A1 (en) | 2003-12-22 | 2008-11-20 | Maria Fardis | 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity |
BRPI0418031A (pt) * | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
CN1950383B (zh) * | 2003-12-30 | 2010-06-09 | 吉里德科学公司 | 用于治疗病毒性疾病的膦酸酯、单膦酸酰胺化物、双膦酸酰胺化物 |
US20050239753A1 (en) * | 2004-01-21 | 2005-10-27 | Gilead Sciences, Inc. | Methods of inhibition of MMTV-like viruses |
US8432394B1 (en) | 2004-05-14 | 2013-04-30 | Nvidia Corporation | Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline |
US8411105B1 (en) | 2004-05-14 | 2013-04-02 | Nvidia Corporation | Method and system for computing pixel parameters |
US7079156B1 (en) | 2004-05-14 | 2006-07-18 | Nvidia Corporation | Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline |
US8416242B1 (en) | 2004-05-14 | 2013-04-09 | Nvidia Corporation | Method and system for interpolating level-of-detail in graphics processors |
KR20070029196A (ko) | 2004-06-08 | 2007-03-13 | 메타베이시스 테라퓨틱스, 인크. | 고리 에스테르의 루이스 산 매개 합성 |
ES2720618T3 (es) * | 2004-07-27 | 2019-07-23 | Gilead Sciences Inc | Análogos de fosfonato de compuestos de inhibidores de VIH |
US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
JP2008535862A (ja) | 2005-04-08 | 2008-09-04 | キメリクス,インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
CN100359315C (zh) * | 2005-05-26 | 2008-01-02 | 林维宣 | 兽药残留能力验证样品及制备方法 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
CN100396689C (zh) * | 2006-03-07 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物 |
CN101442994B (zh) | 2006-05-16 | 2013-03-06 | 吉里德科学公司 | 用于治疗恶性血液病的方法和组合物 |
ES2532502T3 (es) | 2006-07-12 | 2015-03-27 | Mylan Laboratories Limited | Proceso para la preparación de tenofovir |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8105489B2 (en) * | 2007-06-26 | 2012-01-31 | The University Of Wyoming Research Corporation | Treatment and prevention systems for acid mine drainage and halogenated contaminants |
US8441497B1 (en) * | 2007-08-07 | 2013-05-14 | Nvidia Corporation | Interpolation of vertex attributes in a graphics processor |
WO2009094190A2 (en) * | 2008-01-25 | 2009-07-30 | Chimerix, Inc. | Methods of treating viral infections |
TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
EP2937356A1 (en) | 2008-04-25 | 2015-10-28 | Cipla Limited | Crystalline form of tenofovir disoproxil and a process for its preparation |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
BRPI0913677A2 (pt) * | 2008-07-02 | 2015-12-15 | Idenix Pharmaceuticals Inc | composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto |
UA103329C2 (ru) | 2008-07-08 | 2013-10-10 | Гилиад Сайенсиз, Инк. | Соли соединений-ингибиторов вич |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CL2009002206A1 (es) * | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
CA2773773C (en) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
DK2534150T3 (en) | 2010-02-12 | 2017-06-12 | Chimerix Inc | METHODS OF TREATING VIRUS INFECTION |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
MX2012011222A (es) | 2010-04-01 | 2013-01-18 | Centre Nat Rech Scient | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. |
US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
NZ611438A (en) | 2010-12-10 | 2015-06-26 | Sigmapharm Lab Llc | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs |
ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2012154698A2 (en) * | 2011-05-06 | 2012-11-15 | Mckenna Charles E | Method to improve antiviral activity of nucleotide analogue drugs |
ES2629913T3 (es) * | 2011-05-19 | 2017-08-16 | Gilead Sciences, Inc. | Procesos e intermediarios para la preparación de agentes anti-VIH |
AU2014271320B2 (en) * | 2011-08-16 | 2017-02-23 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
AU2012296622C1 (en) * | 2011-08-16 | 2017-02-16 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
CN104244945B (zh) | 2011-09-16 | 2016-08-31 | 吉利德制药有限责任公司 | 用于治疗hcv的方法 |
AU2014215976B2 (en) * | 2011-10-07 | 2016-06-30 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
AU2016228317B2 (en) * | 2011-10-07 | 2018-07-19 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
US8664386B2 (en) * | 2011-10-07 | 2014-03-04 | Gilead Sciences, Inc. | Methods for preparing anti-viral nucleotide analogs |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013095684A1 (en) | 2011-12-22 | 2013-06-27 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
MD20140091A2 (ro) | 2012-02-03 | 2015-01-31 | Gilead Sciences, Inc. | Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale |
WO2013115916A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
CN107312039B (zh) * | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
GB201215696D0 (en) * | 2012-09-03 | 2012-10-17 | Ithemba Pharmaceuticals Pty Ltd | A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA) |
AU2013340559B2 (en) * | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
CN102899327B (zh) * | 2012-11-06 | 2014-06-11 | 清华大学深圳研究生院 | 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用 |
JP6297582B2 (ja) * | 2012-11-16 | 2018-03-20 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 |
CN103848869B (zh) * | 2012-12-04 | 2016-12-21 | 上海医药工业研究院 | 制备替诺福韦的方法 |
CN103848868B (zh) * | 2012-12-04 | 2017-04-12 | 蚌埠丰原涂山制药有限公司 | 制备替诺福韦的方法 |
DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
CN104072539B (zh) * | 2013-03-25 | 2017-03-29 | 安徽贝克联合制药有限公司 | 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用 |
WO2014187314A1 (zh) * | 2013-05-21 | 2014-11-27 | 成都先导药物开发有限公司 | 一种药物靶标捕获方法 |
WO2014195724A1 (en) | 2013-06-07 | 2014-12-11 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
WO2015040640A2 (en) * | 2013-09-20 | 2015-03-26 | Laurus Labs Private Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
EP2860185A1 (en) | 2013-10-09 | 2015-04-15 | Zentiva, k.s. | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof |
IN2013CH05455A (el) * | 2013-11-27 | 2015-08-07 | Laurus Labs Private Ltd | |
IN2014MU00118A (el) * | 2014-01-14 | 2015-08-28 | Mylan Lab Ltd | |
TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
CN104804042B (zh) * | 2014-01-24 | 2018-01-19 | 齐鲁制药有限公司 | 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途 |
US9463194B2 (en) | 2014-02-05 | 2016-10-11 | Gilead Sciences, Inc. | Methods of treating patients co-infected with HIV and tuberculosis |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
CN105814068B (zh) * | 2014-02-27 | 2017-08-04 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
CN105001262B (zh) * | 2014-04-18 | 2017-09-01 | 四川海思科制药有限公司 | 芳基取代的磷酰胺类衍生物及其在医学上的应用 |
CN105531281B (zh) * | 2014-04-21 | 2017-12-15 | 四川海思科制药有限公司 | 一种核苷类似物及其中间体的制备方法 |
CN105085571A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺复合物及其制备方法和用途 |
CN105518012B (zh) * | 2014-06-25 | 2018-03-02 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
KR101703258B1 (ko) | 2014-12-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
KR101703257B1 (ko) | 2014-09-30 | 2017-02-06 | 한미정밀화학주식회사 | 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법 |
CN106687467A (zh) * | 2014-09-30 | 2017-05-17 | 韩美精密化学株式会社 | 高纯度(r)‑9‑[2‑(磷酰甲氧基)丙基]腺嘌呤的制备方法 |
EP3203995A4 (en) | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
CN105646584B (zh) * | 2014-11-12 | 2018-09-28 | 四川海思科制药有限公司 | 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途 |
CN104558036A (zh) * | 2014-12-11 | 2015-04-29 | 杭州和泽医药科技有限公司 | 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法 |
EP3240793A1 (en) | 2015-01-03 | 2017-11-08 | Mylan Laboratories Ltd. | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
US20180148774A1 (en) * | 2015-05-16 | 2018-05-31 | Godx, Inc | Point of need testing device and methods of use thereof |
CN106188139B (zh) | 2015-05-29 | 2020-02-18 | 江苏天士力帝益药业有限公司 | 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用 |
CZ2015384A3 (cs) | 2015-06-05 | 2016-12-14 | Zentiva, K.S. | Pevné formy Tenofovir alafenamidu |
AU2016277859B2 (en) * | 2015-06-17 | 2019-08-01 | Gilead Sciences, Inc. | Co-crystals, salts and solid forms of tenofovir alafenamide |
SI4070787T1 (sl) | 2015-06-30 | 2023-07-31 | Gilead Sciences, Inc. | Farmacevtske formulacije |
TWI639598B (zh) | 2015-08-10 | 2018-11-01 | 美商默沙東藥廠 | 抗病毒β-胺基酸酯磷酸二醯胺化合物 |
TWI620754B (zh) * | 2015-08-26 | 2018-04-11 | Method for preparing amino phosphate derivative and preparation method thereof | |
TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
TWI616453B (zh) * | 2015-08-27 | 2018-03-01 | Substituted amino acid thioester compounds, compositions and uses thereof | |
WO2017037608A1 (en) * | 2015-08-28 | 2017-03-09 | Laurus Labs Private Limited | Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof |
LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
TWI737647B (zh) | 2015-11-09 | 2021-09-01 | 美商基利科學股份有限公司 | 用於治療人類免疫缺乏病毒之治療組合物 |
CN106800573B (zh) * | 2015-11-25 | 2020-03-10 | 四川海思科制药有限公司 | 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用 |
US10745428B2 (en) | 2015-12-10 | 2020-08-18 | Idenix Pharmaceuticals Llc | Antiviral phosphodiamide prodrugs of tenofovir |
CN106866737B (zh) * | 2015-12-11 | 2020-11-20 | 南京圣和药物研发有限公司 | 膦酸衍生物及其应用 |
EP3390413B1 (en) | 2015-12-15 | 2020-08-19 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
CN107709288A (zh) * | 2016-02-03 | 2018-02-16 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
CN108350007B (zh) * | 2016-03-01 | 2020-04-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的腺嘌呤化合物及其药物组合物 |
CN107179355B (zh) * | 2016-03-11 | 2021-08-10 | 广东东阳光药业有限公司 | 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法 |
CZ2016156A3 (cs) | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
CN107226826A (zh) * | 2016-03-25 | 2017-10-03 | 江苏奥赛康药业股份有限公司 | 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物 |
CN109476689B (zh) | 2016-06-05 | 2021-09-03 | 上海诚妙医药科技有限公司 | 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途 |
CN107698621A (zh) * | 2016-06-20 | 2018-02-16 | 杭州和泽医药科技有限公司 | 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用 |
WO2017221189A1 (en) * | 2016-06-22 | 2017-12-28 | Laurus Labs Limited | An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof |
CN106317116A (zh) * | 2016-08-19 | 2017-01-11 | 张红利 | 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物 |
CA3021227C (en) | 2016-08-19 | 2020-11-03 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2018039157A1 (en) | 2016-08-25 | 2018-03-01 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
CN106380484A (zh) * | 2016-08-29 | 2017-02-08 | 杭州百诚医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的新晶型及其制备方法 |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
EP3532069A4 (en) | 2016-10-26 | 2020-05-13 | Merck Sharp & Dohme Corp. | ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS |
CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
CN108129514A (zh) * | 2016-12-01 | 2018-06-08 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物的单一异构体及其医药用途 |
BR112019013017A2 (pt) | 2016-12-22 | 2020-01-14 | Idenix Pharmaceuticals Llc | compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos |
CA3046029A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antiviral benzyl-amine phosphodiamide compounds |
WO2018115046A1 (en) | 2016-12-23 | 2018-06-28 | Sandoz Ag | Crystalline solid forms of tenofovir alafenamide |
AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
WO2018153977A1 (en) | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
RU2647576C1 (ru) * | 2017-02-28 | 2018-03-16 | Васильевич Иващенко Александр | Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения |
CN106866739B (zh) * | 2017-03-10 | 2018-11-02 | 华东师范大学 | 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法 |
US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
WO2018175325A1 (en) | 2017-03-20 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv post-exposure prophylaxis |
CN108794530A (zh) * | 2017-04-26 | 2018-11-13 | 上海医药工业研究院 | 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途 |
AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
KR102379965B1 (ko) * | 2017-05-19 | 2022-03-29 | 주식회사 종근당 | 테노포비르의 효율적인 제조방법 |
CN107266499B (zh) * | 2017-06-05 | 2019-07-02 | 珠海优润医药科技有限公司 | 一种抗病毒化合物及其制备方法 |
EP3641733A1 (en) | 2017-06-30 | 2020-04-29 | Cipla Limited | Pharmaceutical compositions |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
WO2019021319A1 (en) | 2017-07-27 | 2019-01-31 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
CN107655987B (zh) * | 2017-09-08 | 2020-11-03 | 厦门蔚扬药业有限公司 | 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法 |
CN107522743A (zh) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法 |
EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
WO2019130354A1 (en) | 2017-12-30 | 2019-07-04 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
WO2019139920A1 (en) * | 2018-01-10 | 2019-07-18 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
EP3737359A4 (en) * | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS |
KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
CA3090280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
CN108101943B (zh) * | 2018-02-28 | 2020-11-24 | 顾世海 | 一种替诺福韦前药或可药用盐及其在医药上的应用 |
CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のためのカプシド阻害剤 |
WO2020018399A1 (en) | 2018-07-19 | 2020-01-23 | Merck Sharp & Dohme Corp. | Phosphinic amide prodrugs of tenofovir |
CN112996517A (zh) | 2018-09-19 | 2021-06-18 | 吉利德科学公司 | 预防hiv的整合酶抑制剂 |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
CA3146263A1 (en) | 2019-07-19 | 2021-01-28 | Jose Gerardo Garcia Lerma | Hiv pre-exposure prophylaxis |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CA3152013A1 (en) * | 2019-08-22 | 2021-02-25 | Emory University | Nucleoside prodrugs and uses related thereto |
EP4031141A4 (en) * | 2019-09-20 | 2023-10-18 | Abbott Rapid Diagnostics International Unlimited Company | ANTIBODIES AGAINST TENOFOVIR AND ITS DERIVATIVES |
CN114727999A (zh) | 2019-11-26 | 2022-07-08 | 吉利德科学公司 | 用于预防hiv的衣壳抑制剂 |
TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
WO2021165995A1 (en) | 2020-02-20 | 2021-08-26 | Cipla Limited | Novel salts and/or co-crystals of tenofovir alafenamide |
AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021202669A2 (en) | 2020-04-01 | 2021-10-07 | Reyoung Corporation | Nucleoside and nucleotide conjugate compounds and uses thereof |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
CN115605492A (zh) | 2020-04-21 | 2023-01-13 | 配体制药股份有限公司(Us) | 核苷酸前药化合物 |
TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
CN113970612B (zh) * | 2020-07-22 | 2023-08-01 | 北京四环制药有限公司 | 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法 |
TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
CN112336695B (zh) * | 2020-09-28 | 2023-01-03 | 华北制药华坤河北生物技术有限公司 | 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法 |
AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
US11667656B2 (en) | 2021-01-27 | 2023-06-06 | Apotex Inc. | Crystalline forms of Tenofovir alafenamide |
CN113214322B (zh) * | 2021-04-30 | 2022-10-25 | 山东立新制药有限公司 | 替诺福韦绿色环保的制备方法 |
WO2022251594A1 (en) * | 2021-05-27 | 2022-12-01 | Antios Therapeutics, Inc. | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
CN114369120A (zh) * | 2022-01-28 | 2022-04-19 | 石家庄龙泽制药股份有限公司 | 一种丙酚替诺福韦关键中间体的制备方法 |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
US5650510A (en) | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
US5057301A (en) | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
US5053215A (en) * | 1988-05-26 | 1991-10-01 | University Of Florida | NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5688778A (en) | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
JP2648516B2 (ja) | 1989-07-27 | 1997-09-03 | ダイセル化学工業株式会社 | 立体異性体の分離法 |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
JP2925753B2 (ja) | 1990-02-23 | 1999-07-28 | ダイセル化学工業株式会社 | 光学異性体の分離方法 |
US5302585A (en) | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
FI911875A (fi) * | 1990-04-20 | 1991-10-21 | Bristol Myers Squibb Co | Kirala 2-(fosfonometoxi) propylguaniner som antivirala aemnen. |
SK280313B6 (sk) | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
CS276072B6 (en) | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF |
CA2088363C (en) | 1990-08-10 | 2002-05-28 | Purushotham Vemishetti | Process for the preparation of nucleotides |
DK0481214T3 (da) | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5208221A (en) * | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
CZ284678B6 (cs) | 1991-05-20 | 1999-01-13 | Ústav Organické Chemie A Biochemie Avčr | Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití |
US5498752A (en) | 1991-08-22 | 1996-03-12 | Daicel Chemical Industries, Ltd. | Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution |
JP3010816B2 (ja) | 1991-08-22 | 2000-02-21 | ダイセル化学工業株式会社 | 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法 |
CZ287745B6 (cs) | 1991-10-11 | 2001-01-17 | Ústav organické chemie a biochemie AV ČR | Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
CA2171868A1 (en) * | 1993-09-17 | 1995-03-23 | Petr Alexander | Method for dosing therapeutic compounds |
US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
JP4086314B2 (ja) | 1993-09-17 | 2008-05-14 | ギリアード サイエンシーズ, インコーポレイテッド | ヌクレオチドアナログ |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
DK0828749T3 (da) * | 1995-05-26 | 2003-10-27 | Genta Inc | Fremgangsmåder til syntese af organophosphorderivater |
US5717095A (en) * | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
NZ325704A (en) | 1995-12-29 | 2000-02-28 | Gilead Sciences Inc | Nucleotide analogs |
US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
JP4033494B2 (ja) * | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ, インコーポレイテッド | ヌクレオチドアナログ |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
AU756793B2 (en) * | 1997-07-25 | 2003-01-23 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
KR100700087B1 (ko) | 1997-07-25 | 2007-03-28 | 길리애드 사이언시즈, 인코포레이티드 | 뉴클레오티드 동족체의 제조 방법 |
CA2312975C (en) * | 1997-12-17 | 2012-08-21 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
DE69900841T2 (de) * | 1998-01-23 | 2002-10-02 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
AU755564B2 (en) * | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US6169879B1 (en) * | 1998-09-16 | 2001-01-02 | Webtv Networks, Inc. | System and method of interconnecting and using components of home entertainment system |
GB9821058D0 (en) † | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
TWI230618B (en) | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
CA2362662A1 (en) † | 1999-02-12 | 2000-08-17 | Glaxo Group Limited | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents |
JP4651264B2 (ja) * | 2000-07-21 | 2011-03-16 | ギリアード サイエンシーズ, インコーポレイテッド | ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。 |
JP4387669B2 (ja) * | 2000-10-13 | 2009-12-16 | ザイジェン エス.アー. | 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達 |
US20020119433A1 (en) * | 2000-12-15 | 2002-08-29 | Callender Thomas J. | Process and system for creating and administering interview or test |
-
2001
- 2001-07-20 JP JP2002514146A patent/JP4651264B2/ja not_active Expired - Lifetime
- 2001-07-20 HR HRP20160074AA patent/HRP20160074B1/hr not_active IP Right Cessation
- 2001-07-20 US US10/333,107 patent/US20040018150A1/en not_active Abandoned
- 2001-07-20 AU AU8294101A patent/AU8294101A/xx active Pending
- 2001-07-20 CN CNB018131611A patent/CN1291994C/zh not_active Expired - Lifetime
- 2001-07-20 CN CNB2004100978453A patent/CN100402539C/zh not_active Expired - Lifetime
- 2001-07-20 DK DK13164300.9T patent/DK2682397T3/da active
- 2001-07-20 EP EP13164300.9A patent/EP2682397B1/en not_active Expired - Lifetime
- 2001-07-20 HU HU0301307A patent/HU230960B1/hu active Protection Beyond IP Right Term
- 2001-07-20 WO PCT/US2001/023104 patent/WO2002008241A2/en active Application Filing
- 2001-07-20 CA CA2416757A patent/CA2416757C/en not_active Expired - Lifetime
- 2001-07-20 NZ NZ523438A patent/NZ523438A/en not_active IP Right Cessation
- 2001-07-20 EP EP01961695.2A patent/EP1301519B2/en not_active Expired - Lifetime
- 2001-07-20 PT PT1961695T patent/PT1301519E/pt unknown
- 2001-07-20 OA OA1200300003A patent/OA12393A/en unknown
- 2001-07-20 TR TR2003/00055T patent/TR200300055T2/xx unknown
- 2001-07-20 KR KR1020067020061A patent/KR100749160B1/ko active IP Right Grant
- 2001-07-20 BR BR0112646A patent/BRPI0112646B8/pt active IP Right Grant
- 2001-07-20 KR KR1020037000872A patent/KR100767432B1/ko active Protection Beyond IP Right Term
- 2001-07-20 MX MXPA03000587A patent/MXPA03000587A/es active IP Right Grant
- 2001-07-20 PL PL360490A patent/PL213214B1/pl unknown
- 2001-07-20 AP APAP/P/2003/002724A patent/AP1466A/en active
- 2001-07-20 PT PT131643009T patent/PT2682397T/pt unknown
- 2001-07-20 LT LTEP13164300.9T patent/LT2682397T/lt unknown
- 2001-07-20 CZ CZ2003-413A patent/CZ304886B6/cs unknown
- 2001-07-20 IL IL15365801A patent/IL153658A0/xx active Protection Beyond IP Right Term
- 2001-07-20 EA EA200300188A patent/EA004926B1/ru active Protection Beyond IP Right Term
- 2001-07-20 CA CA2893174A patent/CA2893174A1/en not_active Abandoned
- 2001-07-20 SI SI200131061T patent/SI2682397T1/sl unknown
- 2001-07-20 SI SI200131040T patent/SI1301519T1/sl unknown
- 2001-07-20 US US09/909,560 patent/US20020119443A1/en not_active Abandoned
- 2001-07-20 CZ CZ2013-310A patent/CZ304734B6/cs not_active IP Right Cessation
- 2001-07-20 EP EP17160970.4A patent/EP3235823A1/en not_active Withdrawn
- 2001-07-20 UA UA2003021482A patent/UA75889C2/uk unknown
- 2001-07-20 DK DK01961695.2T patent/DK1301519T4/da active
- 2001-07-20 CA CA2725819A patent/CA2725819C/en not_active Expired - Lifetime
- 2001-07-20 ES ES13164300.9T patent/ES2627903T3/es not_active Expired - Lifetime
- 2001-07-20 ES ES01961695T patent/ES2536972T5/es not_active Expired - Lifetime
- 2001-07-20 EE EEP200300029A patent/EE05366B1/xx active Protection Beyond IP Right Term
- 2001-07-20 AU AU2001282941A patent/AU2001282941C1/en active Active
- 2001-07-20 NZ NZ535408A patent/NZ535408A/en not_active IP Right Cessation
- 2001-07-20 NZ NZ536942A patent/NZ536942A/xx not_active IP Right Cessation
-
2002
- 2002-12-19 ZA ZA2002/10271A patent/ZA200210271B/en unknown
-
2003
- 2003-01-17 IS IS6689A patent/IS2985B/is unknown
- 2003-01-20 NO NO20030270A patent/NO336718B1/no active Protection Beyond IP Right Term
- 2003-01-24 HR HRP20030047AA patent/HRP20030047B1/hr not_active IP Right Cessation
- 2003-01-28 US US10/354,207 patent/US20030219727A1/en not_active Abandoned
- 2003-02-19 BG BG107572A patent/BG66037B1/bg unknown
- 2003-08-15 HK HK03105871.0A patent/HK1054238A1/xx active IP Right Maintenance
-
2004
- 2004-02-24 US US10/785,497 patent/US20060024659A1/en not_active Abandoned
- 2004-03-11 US US10/798,692 patent/US7390791B2/en active Active
-
2005
- 2005-01-06 US US11/031,228 patent/US20050159392A1/en not_active Abandoned
- 2005-01-06 US US11/031,251 patent/US20050124584A1/en not_active Abandoned
- 2005-01-06 US US11/031,252 patent/US20050124585A1/en not_active Abandoned
- 2005-01-06 US US11/031,250 patent/US20050124583A1/en not_active Abandoned
- 2005-10-18 AU AU2005225039A patent/AU2005225039B2/en not_active Expired
-
2008
- 2008-04-28 US US12/110,829 patent/US7803788B2/en not_active Expired - Fee Related
- 2008-10-16 JP JP2008267991A patent/JP5063554B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-16 JP JP2010095542A patent/JP5111551B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-08 JP JP2011050854A patent/JP2011140506A/ja not_active Withdrawn
-
2012
- 2012-04-23 NO NO20120466A patent/NO20120466L/no not_active Application Discontinuation
-
2013
- 2013-12-20 NO NO20131717A patent/NO20131717L/no unknown
-
2015
- 2015-07-10 NO NO20150909A patent/NO20150909L/no not_active Application Discontinuation
-
2016
- 2016-04-05 LT LTPA2016009C patent/LTC1301519I2/lt unknown
- 2016-04-07 BE BE2016C018C patent/BE2016C018I2/fr unknown
- 2016-04-11 FR FR16C0013C patent/FR16C0013I2/fr active Active
- 2016-04-12 CY CY2016008C patent/CY2016008I1/el unknown
- 2016-04-14 LU LU93029C patent/LU93029I2/xx unknown
- 2016-04-19 NO NO2016006C patent/NO2016006I1/no unknown
- 2016-04-22 NL NL300803C patent/NL300803I2/nl unknown
-
2017
- 2017-06-28 CY CY20171100687T patent/CY1119411T1/el unknown
-
2018
- 2018-03-09 HK HK18103347.4A patent/HK1243711A1/zh unknown
-
2019
- 2019-05-09 HU HUS1900027C patent/HUS1900027I1/hu unknown
-
2023
- 2023-02-03 NO NO2023006C patent/NO2023006I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119411T1 (el) | Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων | |
DK0481214T3 (da) | Prolægemidler af phosphonater | |
CY1105866T1 (el) | Αναλογα ταμανταρινης και διδεμνινης και μεθοδοι παρασκευης και χρησης αυτων | |
CY1106207T1 (el) | Αντιιικα παραγωγα νουκλεοζιτων | |
CY1107758T1 (el) | Πολυμορφα ενος αναλογου εποθεινολης | |
CY1121218T1 (el) | Χημικες ενωσεις | |
MX2009012433A (es) | Azido nucleosidos de purina para el tratamiento de infecciones virales. | |
CY1108010T1 (el) | Παραγωγα ξανθινης, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα | |
ES2139567T3 (es) | Secuencias nucleotidicas procedentes del genoma de retrovirus del tipo vih-1 y sus aplicaciones para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones producidas por estos virus. | |
CY1108355T1 (el) | Συνθεσεις και μεθοδοι για συνδυασμενη αντι-ιικη θεραπεια | |
CY1114643T1 (el) | Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων | |
CY1113647T1 (el) | Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια | |
PT1309589E (pt) | Compostos de ureia e metodos de utilizacao | |
CY1110019T1 (el) | Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες | |
DK1628685T3 (da) | Antivirale phosphonatanaloge | |
CY1116164T1 (el) | Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου | |
CY1111567T1 (el) | Ενδιαμεσα διβενζο (b,f) αζεπινης | |
CY1116523T1 (el) | Προφαρμακα αναλογων φωσφονικου νουκλεοτιδιου και μεθοδοι για επιλογη και κατασκευη αυτων | |
UY26988A1 (es) | Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos. | |
AR101679A2 (es) | Composiciones para el tratamiento antiviral combinado |